On Tuesday, CRISPR Therapeutics got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 93.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 at the beginning of a new price run.
See How IBD Helps You Make More Money In Stocks
CRISPR Therapeutics is working on a cup without handle with a 76.97 buy point. But keep an eye on this stock as it could be starting to form a handle. If that happens, see if it can break out in volume at least 40% above average.
CRSP Earnings
CRISPR Therapeutics showed 0% earnings growth in its most recent report, while sales growth came in at -100%. The next quarterly results are expected on or around Feb. 13.
The company earns the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Alkermes and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
